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ABSTRACT
Background: Signiﬁcant gaps exist between guidelines-
recommended therapies for cardiovascular disease
prevention and current practice. Fixed-dose combination
pills (‘polypills’) potentially improve adherence to
therapy. This study is a preference study undertaken in
conjunction with a clinical trial of a polypill and seeks to
examine the underlying reasons for variations in
treatment adherence to recommended therapy.
Methods/design: A preference study comprising:
(1) Discrete Choice Experiment for patients; and
(2) qualitative study of patients and providers. Both
components will be conducted on participants in the
trial. A joint model combining the observed adherence
in the clinical trial (revealed preference) and the Discrete
Choice Experiment data (stated preference) will be
estimated. Estimates will be made of the marginal effect
(importance) of each attribute on overall choice, the
extent to which respondents are prepared to trade-off
one attribute for another and predicted values of the
level of adherence given a ﬁxed set of attributes, and
contextual and socio-demographic characteristics. For
the qualitative study, a thematic analysis will be used as
a means of exploring in depth the preferences and
ultimately provide important narratives on the
experiences and perspectives of individuals with regard
to adherence behaviour.
Ethics and dissemination: Primary ethics approval
was received from Sydney South West Area Health
Service Human Research Ethics Committee (Royal
Prince Alfred Hospital zone). In addition to usual
scientiﬁc forums, the ﬁndings will be reported back to
the communities involved in the studies through site-
speciﬁc reports and oral presentations.
BACKGROUND
Current gap between guidelines and practice
Despite the strong evidence base for therapies
effective at reducing cardiovascular disease
(CVD) morbidity and mortality, and incorpo-
ration of this evidence in therapeutic
guidelines, a substantial gap between recom-
mended treatment and clinical practice exists.
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ARTICLE SUMMARY
Article focus
- To assess patient choices with regard to
adherence to long-term therapy for the preven-
tion of cardiovascular disease in indigenous and
non-indigenous populations.
- To understand, from the perspective of patients
and providers, the factors that inﬂuence how well
guidelines-recommended therapy for cardiovas-
cular disease in indigenous and non-indigenous
populations are implemented.
Key messages
- This is an innovative study using a mixed
methods approach to assess patient medications
adherence that combines data on patients’ stated
preferences and their observed behaviour.
- The study will examine underlying reasons why
adherence outcomes were (or were not) achieved
within the context of a clinical trial of a cardio-
vascular polypill-based strategy and, as such,
serves as a process evaluation.
- The ﬁndings will extrapolate the level of adher-
ence observed in the trial to different ‘real-world’
settings.
Strengths and limitations of this study
- The strengths of the study are that it involves the
innovative application of a preference study
alongside a clinical trial, provides insights into
how patients may respond to factors that
inﬂuence adherence but not necessarily
encounter in a clinical trial setting and addresses
an important public-health issuednamely treat-
ment gaps in relation to cardiovascular-disease
prevention.
- The limitation is that it is a conducted in one
country, Australia, and thus its generalisability
may be limited by prevailing institutional
arrangements.
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Open Access ProtocolThe reasons for the current treatment gaps are
complex, but in addition to poor dissemination and
uptake of guidelines, other factors include: low contin-
uation rates by patients, inequities in health services, and
resistance (by both doctors and patients) to the cost,
complexity and stigmatisation of prescribing four or
more cardiovascular medications. Low medication
adherence rates are a well-documented, highly prevalent
obstacle to successful ongoing prevention and treatment
of chronic diseases such as cardiovascular disease.
1e5
Barriers to adopting guideline recommendations by
doctors may include lack of time, multiplicity and lack of
awareness of guidelines, and insufﬁcient resources to
implement recommendations. From a patient perspec-
tive, non-adherence is associated with taking multiple
medicines and complex dosing regimens.
124 e6 Cost can
be an important contributory factor, and patients can
delay or omit doses and not ﬁll prescriptions as strategies
for cost reduction.
47
Existing study: a randomised controlled trial of a polypill-
based strategy to improve implementation of guidelines for
CVD prevention
The use of ﬁxed-dose combination therapy to prevent
CVD has generated debate since Wald and Law advo-
cated the widespread use of a ‘polypill’ containing
aspirin, a statin, three low-dose blood pressure-lowering
drugs and folic acid for the prevention of CVD events.
8 It
has been proposed that ﬁxed-dose combination pills
may improve adherence by reducing the number and
complexity of dosing regimens for doctors and patients,
and improving access to treatment by reducing costs.
The Kanyini GAP (Guidelines Adherence with the
Polypill) trial, which commenced patient recruitment in
the last quarter of 2009, is a prospective, open, rando-
mised controlled clinical trial (n¼1000) of a polypill-
based strategy compared with usual care among indi-
viduals at high risk of cardiovascular events. Six hundred
indigenous participants are being mainly recruited from
around 10 Aboriginal Medical Service partners within
the Kanyini Vascular Collaboration, while the 400 non-
indigenous participants are being recruited from
general practice sites in New South Wales, Victoria and
Queensland.
The randomised controlled trial (RCT) aims to assess
whether provision of a polypill (containing low-dose
aspirin, a statin and two blood-pressure-lowering medi-
cines) compared with usual cardiovascular medications
improves adherence to indicated therapies and clinical
outcomes among high-risk patients. Participants are
being followed up for an average of 18 months. The
main outcome of interest is adherence to indicated
therapies deﬁned as self-reported current use of anti-
platelet, statin and combination ($2) blood-pressure-
lowering therapy. However, as there are substantial
challenges in reliably measuring adherence, the study is
powered to detect meaningful differences in the bio-
logical proxies of blood pressure and total cholesterol
levels. Details on the study protocol are contained in the
Australian and New Zealand Clinical Trials Registry
(ACTRN12608000583347).
9
Analytical framework: Discrete Choice Experiment as a tool
for assessing therapeutic adherence within a process
evaluation
The polypill strategy is not simply a pharmacological
interventiondpatients’ adherence is likely to be inﬂu-
enced by their preferences and beliefs, the tangible and
intangible costs incurred and the behaviour of providers.
In this respect it can be deﬁned as a complex interven-
tion in which there are ‘several interacting components’
and in which providers and those receiving the inter-
vention are expected to comply with behaviours that
entail a signiﬁcant degree of difﬁculty.
10
The inclusion of a process evaluation alongside a trial
or outcome evaluation of a complex intervention
has been posited as a means of understanding how and
why an intervention might or might not have been
effective.
10e13 Such evaluations utilise qualitative and
quantitative methods and address speciﬁc issues about
an intervention including how it is viewed by partici-
pants; how it was implemented; the distinction between
its various components; the contextual factors that
inﬂuence its effectiveness; its reach in terms of individ-
uals/sites; and variation in effects across subgroups.
11
The ongoing prescription and consumption of the
polypill in the real-world setting relies on patient and
physician choices which in turn are inﬂuenced by the
interplay of physician, patient, therapy, disease, and
health-system characteristics.
14 In this context, a process
evaluation is needed to provide some indication of the
generalisability of the results of the results of the trial to
other settings. The ﬁndings will assist in translating the
results into policy and practice.
We propose to undertake a discrete choice experi-
ment, along with a series of qualitative interviews with
patients, GPs and pharmacists, as a technique to address
these issues. Discrete Choice Experiment (DCE) is based
on the notion, drawn from economic consumer theory,
that individuals’ demand for goods can be decomposed
into preferences for speciﬁc ‘attributes.’
15 For example,
an individual’s demand for a particular drug will be
determined by attributes such as its known efﬁcacy, side
effects, cost and convenience of dosing. However, what
we can observe in practice is choices between particular
goodsdor bundles of such attributes. Accordingly, DCEs
involve the use of surveys in which respondents choose
between alternative goods which vary in the level of their
attributes. For instance, respondents are asked to choose
between Drug Regimen A and Drug Regimen B based on
the description of their attributes provided, assuming all
else to be equal between the options (see table 1). In this
simpliﬁed example, the choice between Regimen A and
Regimen B involves variation across four attributes: efﬁ-
cacy, side effects, cost and dosing. For a particular option
(Regimen A or B) each of these attributes is set at certain
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Adherence preferences in cardiovascular disease prevention‘levels’dhere, the level of efﬁcacy for both options is
equal between A and B for the attributes efﬁcacy and
dosing. The choice is reduced simply to one of cost
versus of side effects (eg, a choice of B over A would
imply that the respondent is willing to pay an extra $75
per month to avoid the side effect of nausea). In prac-
tice, a DCE survey would involve a series of such choices
in which the level of each of the attributes is varied
(table 1).
In designing a DCE, the initial selection of attributes
and their levels can be informed by a literature review or
qualitative study. Typically, DCE surveys conducted in
health have involved choice sets containing four to eight
attributes. Given sufﬁcient variation across all attributes
through the appropriate design, the approach enables,
using multivariate models, estimates of a utility function
in which each attribute and background characteristic of
respondents represents separate parameters. Ultimately,
through the estimation of a utility function, the
approach enables:
< estimates of the individual effect of attributes of the
products being compared (such as efﬁcacy and cost of
different drug regimens) and the background char-
acteristics of the respondents (such as age, sex and
risk factors) on consumers/or patients’ choice of
product (eg, drug regimen A vs B);
< estimates of the degree to which individuals are
willing to trade-off one attribute for anotherdfor
example, how much individuals are willing to pay for
reduction in side-effects from drug therapy;
< the forecasting of patient choices based on given
attributes and respondent characteristicsdfor
example, for a given cost and demographic proﬁle,
what level of demand we can expect for a speciﬁc
product.
Although initially developed in the marketing ﬁeld,
DCEs have been used extensively in healthcare. Given
the potential cross-cultural barriers that may exist with its
deployment in the Kanyini GAP study population,
extensive piloting will be needed in this study.
16
The rationale for the use of DCEs within this process
evaluation is the view that adherence is in essence
a ‘rational choice’dsuch choice entails patients
balancing a range of factors such as perceived efﬁcacy,
cost and side effects.
17 This economic perspective, where
patients are viewed as active agents in decisions regarding
their care and that there may ultimately be good reasons
for non-adherence, potentially provides alternative
insights to often posited ‘medical’ perspectives where
non-adherence is viewed as deviance.
18
We are not aware of the use of DCEs as part of
a process evaluation, despite the increasing recognition
of their value in assessing patient and consumer prefer-
ences in the health-services research literature. Their
role in process evaluation would be based on their
capacity to explain the motivation and behaviour of
agents in the course of an interventiondcomplex or
otherwise. Furthermore, the use of DCE in conjunction
with a clinical trial provides an opportunity for
combining two sources of data. This represents an
important methodological development, as although the
outcomes of a clinical trial reﬂect the actual behaviour of
participants (revealed preference), such behaviour is
constrained by the parameters in which the study takes
place. These constraints on behaviour and the attributes
that may inﬂuence such behaviour that are imposed by
the research design limit the ability to extrapolate to
circumstances which may differ from those existing
within the study. Thus, while clinical trial data involve
a comparison of two ﬁxed options, ‘stated preference’
methods such as DCE have the ﬂexibility to allow for the
construction and testing of hypothetical scenarios. With
appropriate scaling, the data from such studies can be
combined to provide more robust model estimates and
furthermore allow consideration of a wider range of
factors that modify adherence behaviour than stated or
revealed preference data alone.
19 20
The aims of this study are:
1. to assess patient choices with regard to adherence to
long-term therapy for the prevention of cardiovas-
cular disease in indigenous and non-indigenous
populations;
2. to understand, from the perspective of patients and
providers, the factors that inﬂuence how well guide-
lines-recommended therapy for cardiovascular disease
in indigenous and non-indigenous populations is
implemented.
METHODS/DESIGN
This study comprises two inter-related components: (1)
a DCE of patients to determine the factors that inﬂuence
adherence to therapy; and (2) a qualitative study of
patients, general practitioners and pharmacists.
DCE
The DCE will be carried out by interview-administered
survey by a study nurse at the end of each ﬁnal follow-up
visit in the Kanyini GAP trial. This allows us to conduct
the survey as a face-to-face interview (as opposed to the
usual postal self-administered or telephone method).
The advantages of this strategy are that it allows the
interviewer to better explain the tasks involved in the
survey, and it capitalises on access to the participant
afforded by the trial, thereby minimising both the risk of
non-response and the costs associated with administra-
tion. The questionnaire will undergo extensive piloting
Table 1 Example of a Discrete Choice Experiment
question
Drug regimen A Drug regimen B
Efﬁcacy 50% 50%
Side effects Nausea Nil
Cost $25 per month $100 per month
Dosing 1 per day 1 per day
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trialdthis will inform its design, wording and formatting.
Establishing relevant attributes and levels
An initial set of attributes will be established through
a review of the literature on therapeutic adherence and
cardiovascular disease. The aim of this review is to
capture, for potential inclusion as attributes in the DCE
survey, the most important factors likely to inﬂuence
individuals’ adherence behaviour. Speciﬁcally, the task
here will be to: (1) establish a feasible set of attributes for
inclusion in the survey (usually up to eight) and; (2)
establish the levels at which these attributes are set (eg,
the range of cost to the patient might be set from zero to
$100 per month) based on their feasibility in practice.
Questionnaire design
The appropriate combination of attributes and levels to
be posed in the DCE survey will be based on consider-
ation of both the statistical properties of Efﬁcient Choice
(EC) design and pragmatic judgements about the plau-
sibility of the choice sets offered. CI Rose is a recognised
leader in research into such design principles and will
lead this aspect of the study.
It is rarely feasible or efﬁcient to test every combina-
tion of attribute and attribute levels through a ‘full
factorial design,’ and thus an EC approach can be
deployed to establish a ‘fractional factorial design’ that
links statistical efﬁciency to the likely econometric
model, that is, to be estimated from discrete choice data.
Design software package NGene 1.0 will be deployed to
generate such a design. The principle used is the mini-
misation of the correlation in the data for estimation
purposes so that standard errors on parameter estimates
are ultimately minimised.
21 22 Such a design makes use
of prior information about such estimates which can be
derived in this study from data obtained from the initial
piloting as described above.
In addition, the characteristics of the choices posed will
also be inﬂuenced by judgement about the real-life
feasibility of the speciﬁc combinationsdfor example, if
the number of pills taken per day and co-payment are
posed as attributes, then for any choice, it is highly
unrealistic that the co-payment level will be set higher
when the number of pills per day is lower. Thus, the
design will be restricted from allowing such combinations.
From such principles, a survey will be designed in
which a series of choices will be posed between two
unlabelled options representing alternative treatment
regimens. These will vary by attributes that potentially
inﬂuence patient adherence to treatment such as cost,
dosing, whether administered as a polypill or not, side
effects and perceived effectiveness.
DCE survey
The sites for the DCE will be those involved in the
Kanyini GAP RCT. Aboriginal participants are being
mainly recruited from health-service partners
comprising Aboriginal-community-controlled health
services across Australia. The surveys of Aboriginal
participants will be carried out speciﬁcally by an
Aboriginal project ofﬁcer. Non-Aboriginal participants
will be recruited predominantly from general practices
in NSW, Victoria and Queensland.
9
Centres have been selected on the basis of interest in
participating in the study, practice size and location, and
clinical research experience. Sixty per cent of individual
participants will be indigenous. We anticipate that taking
into account attrition of 10% from loss to follow-up and
death, 900 of the original 1000 participants will be
eligible to participate in the survey at ﬁnal follow-up.
One signiﬁcant advantage of conducting the DCE within
the clinical trial is in the potential to access large
numbers of well-motivated respondents. As such, we
anticipate that the response rate to the survey will be
higher than those conventionally encountered in DCE
studies which are generally conducted in a general
population settingdprevious studies conducted in clin-
ical settings have yielded response rates of 90e100%.
23
Assuming a refusal rate of 10%, we would expect 810
respondents. Because each respondent yields multiple
observations based on the number of discrete choice
questions they answer and that most DCE studies in
healthcare have contained nine to 16 choices,
23 we
would thus expect to obtain 7290e12960 observations.
In our experience, previous comparable surveys in
healthcare have been successfully carried out with the
number of participants generally well below 800.
Analysis and interpretation
A post-hoc analysis of the Kanyini GAP RCT will be
undertaken to provide an initial assessment of the
factors inﬂuencing adherence to treatment. As we are
interested in the role not simply of the intervention but
potentially a broader set of covariates in inﬂuencing this
outcomedand because randomisation controls for such
covariatesdthe analysis will be carried out on a pooled
dataset of subjects in both arms of the trial. The
modelling strategy will entail a multivariate logistic
analysis in which adherence will be assessed as a function
of individuals’ background characteristics (such as age,
sex, disease history, Aboriginality), attributes of inter-
vention (eg, copayment and dosing), contextual vari-
ables (eg, urban/rural) and the treatment group to
which the individual was allocated. Adherence as
a primary outcome is assessed in the trial in terms of self-
reported current use of antiplatelet, statin and combi-
nation ($2) blood-pressure-lowering therapy at the end
of follow-up. For modelling purposes, it will be measured
as a dichotomous variable (adherent vs non-adherent) in
which adherence is deﬁned by an individual who reports
$80% compliance with prescribed dosing. This
threshold is based on the minimum required for thera-
peutic response and is consistent with the literature.
24 25
The analysis of the DCE will entail the use of a mixed
multinomial (random parameters) logit (MMNL) model
using a panel size speciﬁcation. A panel speciﬁcation of
the model allows for multiple and potentially correlated
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Adherence preferences in cardiovascular disease preventionobservations provided by the same respondent where the
response to each DCE question represents a single
observation. MMNL models relax certain statistical
assumptions of more commonly used multinomial logit
models and often lead to models that better explain
choice behaviour.
26 Interactions between attributes in the
discrete choice, and between attributes and population
characteristics (eg, age, gender, income, education, PBS
concessional status, previous heart disease and Aborigi-
nality) will be explored in the mixed logit analysis.
Finally, a joint model combining revealed preference
(observed adherence in the clinical trial) and stated
preference data (DCE) will be estimated. Such estima-
tion needs to take into account potential differences in
noise levels in the two datasets through error variance
scaling. Once completed, the parameter estimates on
the rescaled data can be directly compared across data-
sets, and the pooled data can be analysed through
MMNL as above.
20 The estimated models will be subject
to usual diagnostics including goodness of ﬁt and the
level of internal prediction. Analysis of these data will be
undertaken after all the interviews have been conducted.
The analysis will address Aim 1 of the study and will
speciﬁcally provide the following:
< Estimates of the marginal effect (importance) of each
attribute on overall choicedfor example, if a cost
attribute is presented in the DCE, the analysis will
provide an estimate of the relative effect of cost on
adherence to therapy.
< Estimates of marginal rates of substitution between
attributes, giving an indication of the extent to which
respondents are prepared to trade-off one attribute
for anotherdfor example, if cost and side effects are
offered as attributes in the survey, the marginal rate of
substitution between these will reﬂect the additional
cost patients may be willing to accept as a trade-off for
avoiding certain side effects.
< An indication of the predicted values or ‘market
shares’ associated with different parameter levels
within the estimated utility functions. This allows
forecasting of, for instance, the level of adherence
that could be expected given a ﬁxed set of attributes
(eg, cost, effectiveness and side-effects) and contex-
tual and socio-demographic characteristics. This
forecast can be used to inform policy directed at
altering attribute levels to enhance adherence and be
estimated separately across different contexts and
population subgroups.
Qualitative study
A series of interviews with patients and providers
involved in the Kanyini GAP RCT will be carried out to
provide in-depth understanding of the reasons for
adherence/non-adherence to therapy for cardiovascular
disease preventiondas observed within the trial and in
practice, as would be the case beyond the trial setting.
Recruitment of both providers and patients for interview
will be purposive, to maximise variation on criteria such
as location, practice size and degree of participation (for
providers) and location, gender, age and outcomes (for
patients). Background and adherence data obtained
from the trial and DCE will be used to inform this
recruitment. Sampling will continue until no new
themes or categories emerge from the data (so-called
‘thematic saturation’). We anticipate from previous
experience the need to conduct around 20 GP inter-
views, 10 pharmacist interviews and 40 patient interviews
(20 indigenous and 20 non-indigenous)dand this is
reﬂected in our budget estimates. Interviews will be
scheduled to take place after the DCE. The interviews
will be conducted face to face by a project ofﬁcer, with an
Aboriginal project ofﬁcer responsible for conducting the
interviews with Aboriginal participants.
Provider interviews
Participating GPs and pharmacists will be administered
an in-depth interview to explore:
< their views on the advantages, disadvantages, accept-
ability and applicability of the polypill strategy relative
to current practices;
< what variations there were across patient groups in
terms of experience and performance of the polypill
strategy relative to current practices;
< particular incidents when prescription of the polypill
proved helpful for themselves and/or the patient,
and incidents when it was not advantageous;
< how their behaviour within the trial might be
modiﬁed outside the study setting;
< what characteristics of the study setting mean that
behaviour observed within it may not be reﬂective of
provider behaviour in practice;
< broader questions about their perceptions regarding
the factors that either hinder or facilitate patient
adherence to either the polypill strategy or current
prescribed treatments in practice;
< suggestions for interventions or policies to improve
adherence.
Patient interviews
Patient interviews which will be conducted in patients in
both treatment and control groups will be used to
explore in greater depth:
< their views on the beneﬁts, disadvantages and
acceptability of their current treatment (polypill or
usual care);
< reports on speciﬁc instances where changes occurred
to their usual adherence behaviour and the circum-
stances surrounding these;
< the factors that hinder or facilitate their attitude
towards adherence to therapy within the trial;
< the factors that in practice would modify patients’
adherence behaviour from that exhibited in the trial.
Analysis of the interview data will be thematic, and
NVivo 8 will be used to assist with the management of the
data. Coding will be carried out inductively based on the
themes that emerge from the interviews.
27 The analysis
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DP and PSPs 1 and 2) so that themes can be cross-
checked. In accordance with normal qualitative research
practice, analysis will occur concurrently with the inter-
views, and thus themes will be assessed continually in
light of additional data. Such data will be used as
a means of exploring in greater depth the preferences
observed in both the trial and the DCE, and ultimately
provide important narratives on the experiences
and perspectives of individuals with regard to
adherence behaviour. This will form the basis for a set of
stand-alone research ﬁndings (Aim 2).
Consent
Participants in the trial will be provided an information
sheet about the study and asked to sign and date
a consent form. A copy will be given to the participant
and the original retained at each site attached to the
medical records of the participant.
Data management and handling
Data management will be carried out at the George
Institute. The recordings and transcripts from the qual-
itative interviews and completed DCE surveys will be
securely stored with data ﬁles password protected and
accessible only to the study team. These records will be
destroyed after 15 years.
Reporting
In addition to usual scientiﬁc forums, the ﬁndings will be
reported back to the communities involved in the studies
through site-speciﬁc reports and oral presentations.
Study organisation and ethics
The study will be administered by The George Institute,
with the design and conduct overseen by a project
management committee (authors). This committee has
expertise in both large-scale clinical trials and qualitative
research, economic analysis (particularly the use of
DCEs), clinical CVD management, Aboriginal and
Torres Strait Islander health research and health policy.
This study will be subject to oversight from the Scientiﬁc
Steering Committee for that study of the Kanyini-GAP
trial. The study will adhere to National Health and
Medical Research Council and Aboriginal Health &
Medical Research Council ethical guidelines for human
research. Ethics approval for Kanyini-GAP was ﬁrst
granted by Sydney South West Area Health Service
Human Research Ethics Committee (HREC) (Royal
Prince Alfred Hospital zone), and subsequently by rele-
vant HRECs across the country, which are the Aboriginal
Health & Medical Research Council HREC, Cairns and
Hinterland Health Service District HREC, Central
Australian HREC, Metro South Health Service District
HREC and Monash University HREC.
DISCUSSION
Non-adherence represents a major reason for the
signiﬁcant health inequalities that exist for chronic
illnesses in Australia. CVD represents the single largest
public health burden for Australia, and major challenges
in providing preventive therapy of proven effectiveness
remain. Currently a trial is under way assessing a ﬁxed-
dose combination therapy to improve adherence to
therapy. This study will provide an opportunity to add
value to this trial by examining the underlying reasons
why providers and patients may or may not adhere to
recommended guidelines, taking into account the role
of providers, tangible and intangible costs and the
preferences of patients. The ﬁndings of the trial will thus
be extended and quantiﬁed using a DCE to model the
impact of both patient and treatment attributes on
adherence. Methodologically, this use of DCE will
represent a signiﬁcant development in RCT process
evaluation that will generate deep insights into the
preferences and behaviour of individuals and allow
extrapolation to settings that differ from those in which
the trial was conducted. The study will enable policy
makers to model the cost and other attributes of treat-
ment to achieve targeted levels of adherence, under-
stand better the trade-offs in doing so and ultimately
deliver more effectively proven long-term strategies for
the prevention and management of cardiovascular
disease and other chronic illnesses.
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